GHK-Cu (copper peptide)

The evidence base is strongly split by route of administration, and the longevity positioning rests on the weaker half. Topical/cosmetic: this is the better-supported context. There is genuine human data, including a randomised trial of topical copper tripeptide complex on CO2 laser-resurfaced skin (PubMed 16847171), and cosmetic-product RCTs reporting improvements in fine lines, skin density and pigmentation. An interventional trial of topical GHK-Cu gel for acute wound healing is registered on ClinicalTrials.gov (NCT07437586), which itself indicates the question is still open rather than settled. These are dermatological and cosmetic endpoints, not healthspan endpoints. Injectable/systemic longevity: this is where clinics market it and where the evidence is thinnest. A 2026 UNSW review of injectable anti-ageing peptides states there is "some limited evidence GHK-Cu could play a role in collagen production, and wound healing in mice" but that "these findings have not been confirmed in humans". The same review characterises the injectable peptide field generally: evidence "mostly limited to animal studies", human studies "small and short-term", and "no high-quality trials reflecting real-world use", concluding there is not enough quality evidence to support the anti-ageing claims made for peptides. What the evidence does NOT show: no human trial demonstrates that systemic or injectable GHK-Cu extends healthspan, slows biological ageing, improves any validated ageing biomarker, or produces systemic tissue rejuvenation. Much of the enthusiasm derives from gene-expression and mechanistic work (e.g. the frequently cited PMC6073405 review of GHK-Cu gene data), which is hypothesis-generating, not outcome data. Copper is also biologically active and not benign at arbitrary systemic doses, and compounded injectable product carries sterility, identity and dosing uncertainty that regulators in both markets have flagged. Graded "commercial": it is widely sold and heavily marketed for longevity, but the human outcome evidence supporting those specific healthspan claims does not exist. The topical cosmetic evidence is real but does not transfer to the systemic claim.

What it is

Plain-language explainer

Categories

Common questions

What is GHK-Cu (copper peptide)?

The evidence base is strongly split by route of administration, and the longevity positioning rests on the weaker half. Topical/cosmetic: this is the better-supported context. There is genuine human data, including a randomised trial of topical copper tripeptide complex on CO2 laser-resurfaced skin (PubMed 16847171), and cosmetic-product RCTs reporting improvements in fine lines, skin density and pigmentation. An interventional trial of topical GHK-Cu gel for acute wound healing is registered on ClinicalTrials.gov (NCT07437586), which itself indicates the question is still open rather than settled. These are dermatological and cosmetic endpoints, not healthspan endpoints. Injectable/systemic longevity: this is where clinics market it and where the evidence is thinnest. A 2026 UNSW review of injectable anti-ageing peptides states there is "some limited evidence GHK-Cu could play a role in collagen production, and wound healing in mice" but that "these findings have not been confirmed in humans". The same review characterises the injectable peptide field generally: evidence "mostly limited to animal studies", human studies "small and short-term", and "no high-quality trials reflecting real-world use", concluding there is not enough quality evidence to support the anti-ageing claims made for peptides. What the evidence does NOT show: no human trial demonstrates that systemic or injectable GHK-Cu extends healthspan, slows biological ageing, improves any validated ageing biomarker, or produces systemic tissue rejuvenation. Much of the enthusiasm derives from gene-expression and mechanistic work (e.g. the frequently cited PMC6073405 review of GHK-Cu gene data), which is hypothesis-generating, not outcome data. Copper is also biologically active and not benign at arbitrary systemic doses, and compounded injectable product carries sterility, identity and dosing uncertainty that regulators in both markets have flagged. Graded "commercial": it is widely sold and heavily marketed for longevity, but the human outcome evidence supporting those specific healthspan claims does not exist. The topical cosmetic evidence is real but does not transfer to the systemic claim.

How strong is the evidence for GHK-Cu (copper peptide)?

Commercial. It is offered and sold, which is a statement about availability, not about efficacy.

Is GHK-Cu (copper peptide) approved in Singapore?

Health Sciences Authority position on record: Not registered with HSA as a therapeutic product for any indication; I found no HSA document naming GHK-Cu specifically. What is verified: HSA operates a Special Access Route under which licensed hospitals, clinics and retail pharmacies may import unregistered therapeutic products for a named patient, but HSA restricts this to cases of genuine unmet medical need "such as in situations where a registered treatment option is absent" and where the patient would be clinically compromised without it, with separate HSA approval required for each consignment, a three-month per-patient supply cap, and documented informed consent. HSA explicitly does not assess the safety, quality or efficacy of such products; responsibility sits with the prescribing clinician. That framework is a poor fit for elective cosmetic or longevity use, so a clinic offering GHK-Cu in Singapore is most likely relying on physician-prescribed pharmacy compounding rather than on the Special Access Route. I could not verify the precise legal basis any specific Singapore clinic uses, so treat the practical access pathway as unconfirmed.. An evidence grade and a regulatory approval are different questions.

Is GHK-Cu (copper peptide) approved in Australia?

Therapeutic Goods Administration position on record: Not included on the Australian Register of Therapeutic Goods (ARTG) and not TGA-approved for any indication. TGA search results indicate the agency's peptide safety alert names GHK-Cu as an example of an unapproved peptide product, and that the TGA has added unapproved peptide products to its priority compliance focus areas following increased detection of unlawful importation, supply and advertising. IMPORTANT CAVEAT: I attempted to fetch the two relevant TGA pages four times and every attempt timed out or reset, so the specific naming of GHK-Cu by the TGA comes from search-engine summaries of those TGA pages rather than pages I read in full, and should be re-verified before publication. Independently verified from a 2026 UNSW review: regulated injectable peptides in Australia "fall under prescription-only medicine categories" and should only be accessed through a qualified health professional for a legitimate medical indication, with legal penalties for importing or possessing prescription-only peptides without authority. Compounded product is exempt from ARTG inclusion only when extemporaneously compounded for a particular named person. Much of the market circumvents this by selling "research chemicals" labelled not for human consumption while being packaged, dosed and marketed for human use.. An evidence grade and a regulatory approval are different questions.

What else is GHK-Cu (copper peptide) called?

Also known as GHK-Cu, copper tripeptide-1, GHK copper, glycyl-L-histidyl-L-lysine copper, copper tripeptide complex.